Ferran Chuecos

407 total citations
20 papers, 324 citations indexed

About

Ferran Chuecos is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Epidemiology. According to data from OpenAlex, Ferran Chuecos has authored 20 papers receiving a total of 324 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 12 papers in Physiology and 3 papers in Epidemiology. Recurrent topics in Ferran Chuecos's work include Chronic Obstructive Pulmonary Disease (COPD) Research (18 papers), Asthma and respiratory diseases (12 papers) and Respiratory and Cough-Related Research (9 papers). Ferran Chuecos is often cited by papers focused on Chronic Obstructive Pulmonary Disease (COPD) Research (18 papers), Asthma and respiratory diseases (12 papers) and Respiratory and Cough-Related Research (9 papers). Ferran Chuecos collaborates with scholars based in Spain, United Kingdom and United States. Ferran Chuecos's co-authors include Esther García Gil, Cynthia Caracta, Dave Singh, Robert Mróz, Jutta Beier, Anne‐Marie Kirsten, Rosa Segarra, Rosa Lamarca, Paul Jones and Anthony D’Urzo and has published in prestigious journals such as European Respiratory Journal, Thorax and Respiratory Research.

In The Last Decade

Ferran Chuecos

19 papers receiving 310 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ferran Chuecos Spain	9	295	240	18	11	10	20	324
Denise Till Switzerland	7	571 1.9×	489 2.0×	6 0.3×	21 1.9×	16 1.6×	11	595
Donna Reilly United States	6	269 0.9×	243 1.0×	16 0.9×	19 1.7×	9 0.9×	13	308
R. Cameron United Kingdom	10	467 1.6×	382 1.6×	4 0.2×	11 1.0×	8 0.8×	14	506
Fausto De Michele Italy	8	131 0.4×	102 0.4×	3 0.2×	7 0.6×	8 0.8×	17	188
Pekka Saarelainen Finland	5	302 1.0×	317 1.3×	32 1.8×	5 0.5×		6	355
Cristina M. Bastardo United Kingdom	7	245 0.8×	191 0.8×	11 0.6×	29 2.6×		9	290
Tomasz Polanowski Sweden	6	421 1.4×	339 1.4×	3 0.2×	4 0.4×	11 1.1×	10	441
Richard Forth United Kingdom	11	395 1.3×	411 1.7×	18 1.0×	5 0.5×		24	447
Paula Corcuera Spain	8	131 0.4×	110 0.5×	9 0.5×	16 1.5×	1 0.1×	26	161
Iida Vähätalo Finland	8	122 0.4×	147 0.6×	27 1.5×	9 0.8×		22	184

Countries citing papers authored by Ferran Chuecos

Since Specialization

Citations

This map shows the geographic impact of Ferran Chuecos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ferran Chuecos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ferran Chuecos more than expected).

Fields of papers citing papers by Ferran Chuecos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ferran Chuecos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ferran Chuecos. The network helps show where Ferran Chuecos may publish in the future.

Co-authorship network of co-authors of Ferran Chuecos

This figure shows the co-authorship network connecting the top 25 collaborators of Ferran Chuecos. A scholar is included among the top collaborators of Ferran Chuecos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ferran Chuecos. Ferran Chuecos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

D’Urzo, Anthony, Dave Singh, James F. Donohue, et al.. (2019). <p>Efficacy of aclidinium/formoterol 400/12 µg, analyzed by airflow obstruction severity, age, sex, and exacerbation history: pooled analysis of ACLIFORM and AUGMENT</p>. International Journal of COPD. Volume 14. 479–491. 6 indexed citations

Singh, Dave, Anthony D’Urzo, James F. Donohue, et al.. (2019). <p>An Evaluation Of Single And Dual Long-Acting Bronchodilator Therapy As Effective Interventions In Maintenance Therapy-Naïve Patients With COPD</p>. International Journal of COPD. Volume 14. 2835–2848. 17 indexed citations

Singh, Dave, et al.. (2017). Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol. Respiratory Research. 18(1). 106–106. 28 indexed citations

Beier, Jutta, Robert Mróz, Anne‐Marie Kirsten, Ferran Chuecos, & Esther García Gil. (2017). Improvement in 24-hour bronchodilation and symptom control with aclidinium bromide versus tiotropium and placebo in symptomatic patients with COPD: post hoc analysis of a Phase IIIb study. International Journal of COPD. Volume 12. 1731–1740. 7 indexed citations

Singh, Dave, Anthony D’Urzo, James F. Donohue, et al.. (2017). Efficacy of aclidinium/formoterol: pooled post hoc analysis of patients naïve to COPD maintenance therapy. PA679–PA679. 1 indexed citations

Miravitlles, Marc, et al.. (2016). The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorized by symptom status: a pooled analysis. International Journal of COPD. Volume 11. 2041–2053. 19 indexed citations

Jones, Paul, Nancy Kline Leidy, Asha Hareendran, et al.. (2016). The effect of aclidinium bromide on daily respiratory symptoms of COPD, measured using the Evaluating Respiratory Symptoms in COPD (E-RS: COPD) diary: pooled analysis of two 6-month Phase III studies. Respiratory Research. 17(1). 61–61. 19 indexed citations

Wedzicha, Jadwiga A., Àlvar Agustí, Gavin C. Donaldson, et al.. (2016). Effect of Aclidinium Bromide on Exacerbations in Patients with Moderate-to-Severe COPD: A Pooled Analysis of Five Phase III, Randomized, Placebo-Controlled Studies. COPD Journal of Chronic Obstructive Pulmonary Disease. 13(6). 669–676. 8 indexed citations

McGarvey, Lorcan, Alyn H. Morice, John A. Smith, et al.. (2016). Effect of aclidinium bromide on cough and sputum symptoms in moderate-to-severe COPD in three phase III trials. BMJ Open Respiratory Research. 3(1). e000148–e000148. 16 indexed citations

10.

Miravitlles, Marc, Esther García Gil, Ferran Chuecos, & Rosa Lamarca. (2015). Morning and nighttime symptoms in COPD and efficacy of aclidinium/formoterol in symptomatic vs asymptomatic patients. OA1968–OA1968. 2 indexed citations

11.

D’Urzo, Anthony, Dave Singh, Edward Kerwin, et al.. (2015). Efficacy and safety of aclidinium/formoterol fixed-dose combination in patients with moderate to severe airflow obstruction, stratified by severity. PA1499–PA1499. 3 indexed citations

12.

Jones, Paul, Rosa Lamarca, Ferran Chuecos, et al.. (2014). Characterisation and impact of reported and unreported exacerbations: results from ATTAIN. European Respiratory Journal. 44(5). 1156–1165. 62 indexed citations

13.

McGarvey, Lorcan, Alyn H. Morice, John A. Smith, et al.. (2014). The effect of twice-daily aclidinium bromide on cough and sputum in patients with COPD: Results from phase III studies. 44. 920. 1 indexed citations

14.

Wedzicha, Jadwiga A., Gavin C. Donaldson, Ferran Chuecos, & Esther García Gil. (2014). Effect of aclidinium bromide on exacerbations in patients with moderate-to-severe COPD: Pooled analysis of phase III studies. 44. 1888. 2 indexed citations

15.

Beier, Jutta, Anne‐Marie Kirsten, Robert Mróz, et al.. (2013). Improvement in COPD symptoms with aclidinium bromide vs placebo and tiotropium: A phase IIIb study. European Respiratory Journal. 42(Suppl 57). 184–184. 2 indexed citations

16.

Beier, Jutta, Anne‐Marie Kirsten, Robert Mróz, et al.. (2013). Efficacy and safety of aclidinium bromide vs placebo and tiotropium in COPD: A phase IIIb study. European Respiratory Journal. 42(Suppl 57). 185–185. 1 indexed citations

17.

Beier, Jutta, Anne‐Marie Kirsten, Robert Mróz, et al.. (2013). Efficacy and Safety of Aclidinium Bromide Compared with Placebo and Tiotropium in Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease: Results from a 6-week, Randomized, Controlled Phase Iiib Study. COPD Journal of Chronic Obstructive Pulmonary Disease. 10(4). 511–522. 87 indexed citations

18.

Beier, Jutta, Anne Kirsten, Robert Mróz, et al.. (2012). S51 Efficacy of Aclidinium Bromide Compared with Tiotropium and Placebo in Patients with Moderate to Severe COPD: A Phase IIIb Study: Abstract S51 Table 1. Thorax. 67(Suppl 2). A26.2–A27. 3 indexed citations

19.

Lasseter, Kenneth C., et al.. (2010). Aclidinium Bromide, a Long-Acting Antimuscarinic, Does Not Affect QT Interval in Healthy Subjects. The Journal of Clinical Pharmacology. 51(6). 923–932. 21 indexed citations

20.

Ratner, Paul H., et al.. (2005). Meta-Analysis of the Efficacy of Ebastine 20 mg Compared to Loratadine 10 mg and Placebo in the Symptomatic Treatment of Seasonal Allergic Rhinitis. International Archives of Allergy and Immunology. 138(4). 312–318. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact